HER2+ BC; HER2-low BC, gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC); in 2024 approved for HER2+ solid tumours. This evidence concerns the gene ERBB2 and adenocarcinoma.